Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation. You are requested to kindly take the same on record. Q3FY22 Quarterly Result Announced for Supriya Lifescience Ltd.
Pharmaceuticals company Supriya Lifescience declares Q3FY22 result: Consolidated Revenue for Q3FY22 reported a growth of 44 % (YoY) to Rs. 1,224.4 million as compared to Rs. 850.2 million in Q3FY21. The current quarter performance was driven by very strong demand for anaesthetic, Antiasthmatic and Vitamin therapy. The company expects the demand for these therapies to be strong, also expect demand for antihistamine to pick up going forward. Increase in Q3 sales was also driven by higher penetration in regulated markets like Europe and Latin America Gross Profit for Q3 FY22 stood at Rs. 806.5 million as compared to Rs. 522.7 million in Q3 FY21 , a growth of 54% compared to same quarter last year. EBITDA for Q3 FY22 stood at Rs. 438.2 million and EBITDA Margin stood at 36% as against Rs. 301.6 million in Q3 FY21 (35%), registering a growth of 45% (YoY) PAT for Q3 FY22 stood at Rs. 396.4 million and PAT Margin stood at 32 % in Q3 FY21 as against Rs. 156.9 million in Q3FY21, registering a growth of 153%. Commenting on the Results, Dr. Satish Wagh, Chairman & Managing Director, Supriya Lifescience said, “I would like to thank everyone for the overwhelming support we have received for our IPO. With this support and trust from the investors our IPO was oversubscribed by 71.47 times. The company has shown consistent performance for 9 months FY22 with an operating revenue of Rs 3,525.0 Mn with EBIDTA of Rs 1,424.8 Mn (40 % of Revenue) and PAT of Rs 1,056.0 Mn (30% of revenue). The current quarter performance was driven by very strong demand for anaesthetic, antiasthmatic and Vitamin products. The fourth manufacturing block at our site got operational in May’21. We have also commenced the work for the next manufacturing block which is expected to get operational by FY23. This block will add 310 KL capacity. Two new warehouses for Finished Goods and Raw materials will get operational by Q1 FY23. A new Quality Control laboratory along with state-of-the-art R&D; laboratory will be operational by Q2 FY23. In line with company strategy to penetrate in more regulated markets, we have also applied for registering more products in US, European and Chinese markets “ Result PDF Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
The Board of Directors of the Company at their Meeting held on January 21, 2022 has inter alia, considered and approved the Un-Audited Standalone Financial Results for the Quarter ended December 31, 2021. Please find attached the Press Release with regard to the Un-Audited Financial Results of the Company for the quarter and half year ended December 31, 2021. You are requested to kindly take the same on record. Supriya Lifescience Ltd - 543434 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2021 Along With The Limited Review Report.
The Board of Directors of Company at its meeting held on January 21, 2022, has, inter alia, considered and approved the Unaudited Financial Results of the for the Quarter and nine months ended December 31, 2021 along with the Limited Review Report. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Listing Regulations), we are enclosing a copy of the above mentioned Unaudited Financial Results along with the Limited Review Report of the Auditors. The Financials Results will be published in newspapers as required under the Listing Regulations. The Meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 12.25 p.m. Kindly take the above said information on your records. Supriya Lifescience Ltd - 543434 - Board Meeting Outcome for Outcome Of Board Meeting Held On January 21, 2022 In Accordance With SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
The Board of Directors of Company at its meeting held on January 21, 2022, has, inter alia, considered and approved the Unaudited Financial Results of the for the Quarter and nine months ended December 31, 2021 along with the Limited Review Report. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Listing Regulations), we are enclosing a copy of the above mentioned Unaudited Financial Results along with the Limited Review Report of the Auditors. The Financials Results will be published in newspapers as required under the Listing Regulations. The Meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 12.25 p.m. Kindly take the above said information on your records. Supriya Lifescience Ltd - 543434 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Shweta SinghDesignation :- Company Secretary and Compliance Officer Supriya Lifescience Ltd - 543434 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 , 2021.
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2022 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31 , 2021. Supriya Lifescience Ltd - 543434 - Shareholding for the Period Ended December 31, 2021
Supriya Lifescience Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here Supriya Lifescience Ltd - 543434 - Closure of Trading Window
In accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading in Securities (hereinafter referred to as the "Prohibition of Insider Trading Code"), the Trading window for dealing in the Securities of the Company for all the Designated Persons, as defined in the Code, shall remain closed from January 01, 2022 till the expiry of 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter ended December 31, 2021. The date of the Board Meeting for consideration and approval of the Unaudited Financial results for the Quarter ended December 31, 2021, shall be intimated separately in due course. Kindly take the above said information on your records. Supriya Lifescience Ltd - 543434 - Shareholding for the Period Ended December 23, 2021
Supriya Lifescience Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 23, 2021. For more details, kindly Click here